Incidence and outcome of fungal infections in pediatric small bowel transplant recipients

Transpl Infect Dis. 2010 Dec;12(6):497-504. doi: 10.1111/j.1399-3062.2010.00542.x.

Abstract

Background: Data on the incidence, timing, and outcome of fungal infections in pediatric small bowel transplantation (SBT) are lacking.

Methods: Cases of pediatric SBT from January 2003 through December 2007 were collected. Standard induction was with thymoglobulin and/or basiliximab and maintenance immunosuppression was a tacrolimus-based regimen. Chi-square was used for categorical variables and Kaplan-Meier for survival analyses.

Results: A total 98 recipients were included; 25 patients developed 59 episodes of Candida infections and 4 episodes of invasive aspergillosis (incidence 25.5%, 95% confidence interval [CI] 17%, 34%). Of the Candida species, 37.3% were Candida albicans and 62.7% non-albicans Candida. Of all yeast infections, 66.1% were fungemia, 28.8% intra-abdominal infections, 1.7% empyema, and 3.4% urinary tract infection. Of the Candida intra-abdominal infections, 41.2% developed in the first month post transplantation, while 79.5% of candidemia developed after >6 months. Median time from transplantation to fungal infection was significantly shorter for abdominal infections compared with fungemia (9 versus 163 days; P=0.004). All-cause mortality was not significantly different between patients with and without fungal infections (32.3% versus 29.8%; odds ratio=1.12, 95% CI 0.45, 2.8).

Conclusion: Fungal infections occurred in 25% of SBT recipients and C. albicans was the most common species. Intra-abdominal fungal infections occurred earlier (<1 month) than fungemia (>6 months) post transplantation.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Aspergillosis / epidemiology
  • Aspergillosis / microbiology
  • Aspergillosis / mortality
  • Aspergillus / classification
  • Aspergillus / isolation & purification
  • Candida / classification
  • Candida / isolation & purification
  • Candida albicans / isolation & purification
  • Candidemia / epidemiology
  • Candidemia / microbiology
  • Candidemia / mortality
  • Candidiasis, Invasive / epidemiology
  • Candidiasis, Invasive / microbiology
  • Candidiasis, Invasive / mortality
  • Female
  • Fungemia / epidemiology*
  • Fungemia / microbiology
  • Fungemia / mortality*
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Immunosuppressive Agents
  • Incidence
  • Infant
  • Intestine, Small / transplantation*
  • Male
  • Mycoses / epidemiology*
  • Mycoses / microbiology
  • Mycoses / mortality*
  • Transplants / adverse effects*
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Immunosuppressive Agents